CAJ | 학술논문

常规化疗药物对癌细胞没有选择性，常常会导致严重的副作用。提高这些药物的靶向特异性已成为药物开发的热点方向之一。一些小分子多肽能够靶向作用于特定的受体，因而被用作癌症化疗药物的载体。化疗药物与多肽载体偶联构成新的多肽载体抗肿瘤药物。这些药物具有高特异性、高亲和力和肿瘤渗透力等优点，能够通过细胞表面的特定受体将药物送到靶向癌细胞内，提高抗癌效果、减少副作用和癌细胞的耐药性。多肽载体靶向药物被誉为新一代的靶向特异性的抗肿瘤药物之一。
상규화료약물대암세포몰유선택성，상상회도치엄중적부작용。제고저사약물적파향특이성이성위약물개발적열점방향지일。일사소분자다태능구파향작용우특정적수체，인이피용작암증화료약물적재체。화료약물여다태재체우련구성신적다태재체항종류약물。저사약물구유고특이성、고친화력화종류삼투력등우점，능구통과세포표면적특정수체장약물송도파향암세포내，제고항암효과、감소부작용화암세포적내약성。다태재체파향약물피예위신일대적파향특이성적항종류약물지일。
Conventional cancer chemotherapy has very limited effects due to lacking speciifcity resulting in severe toxic side effects. Certain G protein-coupled receptors (GPCRs) are highly expressed in many tumor cells and tumoral blood veins, with their cognate ligands being peptides. Therefore, these peptides, especially their long-acting analogs, can be applied as drug-delivery vehicles by coupling with cytotoxic agents. These novel cytotoxic peptide-drug conjugates display more potent anti-tumor efifcacy by targeting the cognate receptors while reducing toxic side effects and overcoming multiple drug resistance. This new receptor-targeted approach may provide a promising opportunity for the improvement of cancer treatments.